New vaccines for RSV and bird flu enter human testing

NCT ID NCT07516418

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing several new vaccine formulas against RSV and H5N1 bird flu in 570 healthy adults aged 18 to 49. The main goals are to check safety and see how well the vaccines trigger an immune response. Participants will receive one or two shots and be followed for about 6 to 7 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
RSV and H5 flu vaccines
What this could lead to
If successful, this could lead to new vaccines that protect against RSV and H5N1 bird flu.
What could go wrong
This is an early Phase 1 trial focused on safety, so it is too soon to know if the vaccines will work. Side effects are possible, and the results may not apply to older or younger people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA A(H5N1) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Site # 036006

    RECRUITING

    Taringa, Queensland, 4068, Australia

  • Site # 03610004

    RECRUITING

    South Brisbane, Queensland, 4104, Australia

  • Site # 0361001

    RECRUITING

    Herston, Queensland, 4006, Australia

  • Site # 0361002

    RECRUITING

    Griffith, Queensland, 4222, Australia

  • Site # 0361003

    RECRUITING

    Morayfield, Queensland, 4506, Australia

  • Site # 0361005

    RECRUITING

    Sippy Downs, Queensland, 4556, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.